ST elevation myocardial infarction prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 24: Line 24:
==Overview==
==Overview==


The prognosis for patients with myocardial infarction varies greatly depending upon simple demographic variables like age, the presence of signs and symptoms of heart failure, the duration of symptoms, and comorbidities that are present. Several risk stratification tools have been developed to predict a patient's mortality.  Most of these risk scores are based upon clinical data obtained at the time of admission rather than at the time of discharge. While we as physicians often labor under the impression that we can dramtically change a patient's prognosis, it is noteworthy that 90% of the predictive information regarding 30 day mortality is contained in the following 5 baseline variables: <ref name="pmid7882472">{{cite journal |author=Lee KL, Woodlief LH, Topol EJ, ''et al'' |title=Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators |journal=Circulation |volume=91 |issue=6 |pages=1659–68 |year=1995 |month=March |pmid=7882472 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=7882472}}</ref>
The prognosis for patients with myocardial infarction varies greatly depending upon simple demographic variables like age, the presence of signs and symptoms of heart failure, the duration of symptoms, and comorbidities that are present. Several risk stratification tools have been developed to predict a patient's mortality.  Most of these risk scores are based upon clinical data obtained at the time of admission rather than at the time of discharge.  
 
==Factors associated with a poor prognosis in STEMI==
While we as physicians often labor under the impression that we can dramatically change a patient's prognosis, it is noteworthy that 90% of the predictive information regarding 30 day mortality is contained in the following 5 baseline variables that can be modified to only a limited degree: <ref name="pmid7882472">{{cite journal |author=Lee KL, Woodlief LH, Topol EJ, ''et al'' |title=Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators |journal=Circulation |volume=91 |issue=6 |pages=1659–68 |year=1995 |month=March |pmid=7882472 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=7882472}}</ref>
#Advanced age
#Advanced age
#[[Sinus tachycardia]]
#[[Sinus tachycardia]]
Line 31: Line 34:
#Anterior myocardial infarction location
#Anterior myocardial infarction location


These risk factors for 30 day mortality have been well validated in a multivariate analysis of 41,020 patients in the GUSTO-I trial.  Advanced age was the most significant factor associated with higher 30-day mortality. The rate was only 1.1% in the youngest decile (< 45 years) and climbed to 20.5% in patients > 75 (adjusted chi 2 = 717, P < .0001). Other variables most closely  associated with an increased risk of mortality were lower systolic blood pressure at randomizaiton (chi 2 = 550, P < .0001), higher Killip class (chi 2 = 350, P < .0001), elevated heart rate (chi 2 = 275, P < .0001), and the presence of an anterior infarction (chi 2 = 143, P < .0001). When taken together, '''''these five baseline characteristics contained 90% of the prognostic information'''''. Other significant though less important factors included previous myocardial infarction, height, time to treatment, [[diabetes]], weight, [[smoking]] status, type of thrombolytic, previous bypass surgery, [[hypertension]], and prior cerebrovascular disease. When these variables were combined, a validated model was created which stratified patients according to their mortality risk and accurately estimated the likelihood of death.
As can be surmized, sinus tachycardia, hypotension, Killip class, and anterior MI are all essentially markers of poor pump function on admission.  These risk factors for 30 day mortality have been well validated in a multivariate analysis of 41,020 patients in the GUSTO-I trial.  Advanced age was the most significant factor associated with higher 30-day mortality. The rate was only 1.1% in the youngest decile (< 45 years) and climbed to 20.5% in patients > 75 (adjusted chi 2 = 717, P < .0001). Other variables most closely  associated with an increased risk of mortality were lower systolic blood pressure at randomizaiton (chi 2 = 550, P < .0001), higher Killip class (chi 2 = 350, P < .0001), elevated heart rate (chi 2 = 275, P < .0001), and the presence of an anterior infarction (chi 2 = 143, P < .0001). When taken together, '''''these five baseline characteristics contained 90% of the prognostic information'''''. Other significant though less important factors included previous myocardial infarction, height, time to treatment, [[diabetes]], weight, [[smoking]] status, type of [[thrombolytic]], previous bypass surgery, [[hypertension]], and prior cerebrovascular disease. When these variables were combined, a validated model was created which stratified patients according to their mortality risk and accurately estimated the likelihood of death.


==Other prognostic variables not identified in GUSTO I==
==Other prognostic variables not identified in GUSTO I==
Line 41: Line 44:
There is evidence that case fatality of myocardial infarction has been improving over the years in all ethnicities.<ref name="Liew-2006">{{cite journal | author=Liew R, Sulfi S, Ranjadayalan K, Cooper J, Timmis AD. | title=Declining case fatality rates for acute myocardial infarction in South Asian and white patients in the past 15 years. | journal=Heart | year=2006 | volume=92 | issue=8 | pages=1030-4 | id=PMID 16387823}}</ref>
There is evidence that case fatality of myocardial infarction has been improving over the years in all ethnicities.<ref name="Liew-2006">{{cite journal | author=Liew R, Sulfi S, Ranjadayalan K, Cooper J, Timmis AD. | title=Declining case fatality rates for acute myocardial infarction in South Asian and white patients in the past 15 years. | journal=Heart | year=2006 | volume=92 | issue=8 | pages=1030-4 | id=PMID 16387823}}</ref>


==STEMI risk scores==
The Thrombolysis in Myocardial Infarction TIMI Risk Score <ref>Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031-7. </ref> and TIMI Risk Index <ref>Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358:1571-5. </ref> are two prognostic indices that have been validated in clinical trials and epidemiologic studies to predict 30-day mortality among patients with [[STEMI]].  
The Thrombolysis in Myocardial Infarction TIMI Risk Score <ref>Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031-7. </ref> and TIMI Risk Index <ref>Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358:1571-5. </ref> are two prognostic indices that have been validated in clinical trials and epidemiologic studies to predict 30-day mortality among patients with [[STEMI]].  


Line 49: Line 53:
The TIMI Risk Index incorporates age, HR and SBP (HR x [age/10] x 2/SBP), and has been validated in unselected patients <ref>Ilkhanoff L, O'Donnell CJ, Camargo CA, O'Halloran TD, Giugliano RP, Lloyd-Jones DM. Usefulness of the TIMI Risk Index in predicting short- and long-term mortality in patients with acute coronary syndromes. Am J Cardiol 2005; 96:773-7 </ref>, registries <ref>Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction 3 and 4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:783-9. </ref> and population-based cohorts <ref>Bradshaw PJ, Ko DT, Newman AM, Donovan LR, Tu JV. Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients. Can J Cardiol 2007; 23: 51-6 </ref>
The TIMI Risk Index incorporates age, HR and SBP (HR x [age/10] x 2/SBP), and has been validated in unselected patients <ref>Ilkhanoff L, O'Donnell CJ, Camargo CA, O'Halloran TD, Giugliano RP, Lloyd-Jones DM. Usefulness of the TIMI Risk Index in predicting short- and long-term mortality in patients with acute coronary syndromes. Am J Cardiol 2005; 96:773-7 </ref>, registries <ref>Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction 3 and 4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:783-9. </ref> and population-based cohorts <ref>Bradshaw PJ, Ko DT, Newman AM, Donovan LR, Tu JV. Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients. Can J Cardiol 2007; 23: 51-6 </ref>


Interestingly, although tobacco abuse is a risk factor for CAD and [[STEMI]], smoking is associated with a lower risk of mortality among patients who present with [[STEMI]] <ref>Gourlay SG, Rundle AC, Barron HV. Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2). Nicotine Tob Res 2002; 4: 101-7. </ref> <ref>Weisz G, Cox DA, Garcia E, et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. Am Heart J 2005; 150: 358-64 </ref> This is due, at least in part, to the finding that smokers who present with [[STEMI]] are, on average, at least a decade younger than non-smokers. Smokers more often have involvement of the [[right coronary artery]] rather than the [[left anterior descending artery]] as well. Smokers paradoxically have better myocardial perfusion following reperfusion therapy than non smokers (Kirtane et al).
Interestingly, although tobacco abuse is a risk factor for CAD and [[STEMI]], smoking is associated with a lower risk of mortality among patients who present with [[STEMI]] <ref>Gourlay SG, Rundle AC, Barron HV. Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2). Nicotine Tob Res 2002; 4: 101-7. </ref> <ref>Weisz G, Cox DA, Garcia E, et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. Am Heart J 2005; 150: 358-64 </ref> This is due, at least in part, to the finding that smokers who present with [[STEMI]] are, on average, at least a decade younger than non-smokers. Smokers more often have involvement of the [[right coronary artery]] rather than the [[left anterior descending artery]] as well. Smokers paradoxically have better myocardial perfusion following reperfusion therapy than non smokers.


==References==
==References==

Revision as of 21:29, 7 February 2009

Myocardial infarction
ICD-10 I21-I22
ICD-9 410
DiseasesDB 8664
MedlinePlus 000195
eMedicine med/1567  emerg/327 ped/2520

WikiDoc Resources for ST elevation myocardial infarction prognosis

Articles

Most recent articles on ST elevation myocardial infarction prognosis

Most cited articles on ST elevation myocardial infarction prognosis

Review articles on ST elevation myocardial infarction prognosis

Articles on ST elevation myocardial infarction prognosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on ST elevation myocardial infarction prognosis

Images of ST elevation myocardial infarction prognosis

Photos of ST elevation myocardial infarction prognosis

Podcasts & MP3s on ST elevation myocardial infarction prognosis

Videos on ST elevation myocardial infarction prognosis

Evidence Based Medicine

Cochrane Collaboration on ST elevation myocardial infarction prognosis

Bandolier on ST elevation myocardial infarction prognosis

TRIP on ST elevation myocardial infarction prognosis

Clinical Trials

Ongoing Trials on ST elevation myocardial infarction prognosis at Clinical Trials.gov

Trial results on ST elevation myocardial infarction prognosis

Clinical Trials on ST elevation myocardial infarction prognosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on ST elevation myocardial infarction prognosis

NICE Guidance on ST elevation myocardial infarction prognosis

NHS PRODIGY Guidance

FDA on ST elevation myocardial infarction prognosis

CDC on ST elevation myocardial infarction prognosis

Books

Books on ST elevation myocardial infarction prognosis

News

ST elevation myocardial infarction prognosis in the news

Be alerted to news on ST elevation myocardial infarction prognosis

News trends on ST elevation myocardial infarction prognosis

Commentary

Blogs on ST elevation myocardial infarction prognosis

Definitions

Definitions of ST elevation myocardial infarction prognosis

Patient Resources / Community

Patient resources on ST elevation myocardial infarction prognosis

Discussion groups on ST elevation myocardial infarction prognosis

Patient Handouts on ST elevation myocardial infarction prognosis

Directions to Hospitals Treating ST elevation myocardial infarction prognosis

Risk calculators and risk factors for ST elevation myocardial infarction prognosis

Healthcare Provider Resources

Symptoms of ST elevation myocardial infarction prognosis

Causes & Risk Factors for ST elevation myocardial infarction prognosis

Diagnostic studies for ST elevation myocardial infarction prognosis

Treatment of ST elevation myocardial infarction prognosis

Continuing Medical Education (CME)

CME Programs on ST elevation myocardial infarction prognosis

International

ST elevation myocardial infarction prognosis en Espanol

ST elevation myocardial infarction prognosis en Francais

Business

ST elevation myocardial infarction prognosis in the Marketplace

Patents on ST elevation myocardial infarction prognosis

Experimental / Informatics

List of terms related to ST elevation myocardial infarction prognosis

Cardiology Network

Discuss ST elevation myocardial infarction prognosis further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editors-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

The prognosis for patients with myocardial infarction varies greatly depending upon simple demographic variables like age, the presence of signs and symptoms of heart failure, the duration of symptoms, and comorbidities that are present. Several risk stratification tools have been developed to predict a patient's mortality. Most of these risk scores are based upon clinical data obtained at the time of admission rather than at the time of discharge.

Factors associated with a poor prognosis in STEMI

While we as physicians often labor under the impression that we can dramatically change a patient's prognosis, it is noteworthy that 90% of the predictive information regarding 30 day mortality is contained in the following 5 baseline variables that can be modified to only a limited degree: [1]

  1. Advanced age
  2. Sinus tachycardia
  3. Reduced systolic blood pressure
  4. Heart failure or Killip class of two or greater
  5. Anterior myocardial infarction location

As can be surmized, sinus tachycardia, hypotension, Killip class, and anterior MI are all essentially markers of poor pump function on admission. These risk factors for 30 day mortality have been well validated in a multivariate analysis of 41,020 patients in the GUSTO-I trial. Advanced age was the most significant factor associated with higher 30-day mortality. The rate was only 1.1% in the youngest decile (< 45 years) and climbed to 20.5% in patients > 75 (adjusted chi 2 = 717, P < .0001). Other variables most closely associated with an increased risk of mortality were lower systolic blood pressure at randomizaiton (chi 2 = 550, P < .0001), higher Killip class (chi 2 = 350, P < .0001), elevated heart rate (chi 2 = 275, P < .0001), and the presence of an anterior infarction (chi 2 = 143, P < .0001). When taken together, these five baseline characteristics contained 90% of the prognostic information. Other significant though less important factors included previous myocardial infarction, height, time to treatment, diabetes, weight, smoking status, type of thrombolytic, previous bypass surgery, hypertension, and prior cerebrovascular disease. When these variables were combined, a validated model was created which stratified patients according to their mortality risk and accurately estimated the likelihood of death.

Other prognostic variables not identified in GUSTO I

Other risk factors include, serum creatinine concentration [2], and peripheral vascular disease.[3][4][5]

Left ventricular function as a risk stratifier

Assesment of left ventricular ejection fraction may increase the predictive power of some risk stratification models.[6] The prognostic importance of Q-waves is debated.[7] Prognosis is significantly worsened if a mechanical complication (papillary muscle rupture, myocardial free wall rupture, and so on) were to occur.

There is evidence that case fatality of myocardial infarction has been improving over the years in all ethnicities.[8]

STEMI risk scores

The Thrombolysis in Myocardial Infarction TIMI Risk Score [9] and TIMI Risk Index [10] are two prognostic indices that have been validated in clinical trials and epidemiologic studies to predict 30-day mortality among patients with STEMI.

The TIMI Risk Score incorporates eight clinical variables (age, systolic blood pressure [SBP], heart rate [HR], Killip class, anterior ST elevation or left bundle branch block on electrocardiogram, diabetes mellitus, history of hypertension or angina, low weight and time to treatment >4 hours) and assigns them a point value based on their odds ratio for mortality.

The TIMI Risk Score was developed and validated in clinical trials of fibrinolytic therapy, but it has also been reported to be prognostic in community-based real-world registries [11] as well as elderly patients [12].

The TIMI Risk Index incorporates age, HR and SBP (HR x [age/10] x 2/SBP), and has been validated in unselected patients [13], registries [14] and population-based cohorts [15]

Interestingly, although tobacco abuse is a risk factor for CAD and STEMI, smoking is associated with a lower risk of mortality among patients who present with STEMI [16] [17] This is due, at least in part, to the finding that smokers who present with STEMI are, on average, at least a decade younger than non-smokers. Smokers more often have involvement of the right coronary artery rather than the left anterior descending artery as well. Smokers paradoxically have better myocardial perfusion following reperfusion therapy than non smokers.

References

  1. Lee KL, Woodlief LH, Topol EJ; et al. (1995). "Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators". Circulation. 91 (6): 1659–68. PMID 7882472. Unknown parameter |month= ignored (help)
  2. Gibson CM, Pinto DS, Murphy SA; et al. (2003). "Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality". J. Am. Coll. Cardiol. 42 (9): 1535–43. PMID 14607434. Unknown parameter |month= ignored (help)
  3. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson FA Jr, Granger CB. "Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)." BMJ 2006; 333(7578):1091. PMID 17032691
  4. Weir RA, McMurray JJ, Velazquez EJ. (2006). "Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance". Am J Cardiol. 97 (10A): 13F–25F. PMID 16698331.
  5. Bosch X, Theroux P. (2005). "Left ventricular ejection fraction to predict early mortality in patients with non-ST-segment elevation acute coronary syndromes". Am Heart J. 150 (2): 215–20. PMID 16086920.
  6. Nicod P, Gilpin E, Dittrich H, Polikar R, Hjalmarson A, Blacky A, Henning H, Ross J (1989). "Short- and long-term clinical outcome after Q wave and non-Q wave myocardial infarction in a large patient population". Circulation. 79 (3): 528–36. PMID 2645061.
  7. Liew R, Sulfi S, Ranjadayalan K, Cooper J, Timmis AD. (2006). "Declining case fatality rates for acute myocardial infarction in South Asian and white patients in the past 15 years". Heart. 92 (8): 1030–4. PMID 16387823.
  8. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031-7.
  9. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358:1571-5.
  10. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. Jama 2001; 286:1356-9.
  11. Rathore SS, Weinfurt KP, Foody JM, Krumholz HM. Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients. Am Heart J 2005; 150: 402-10.
  12. Ilkhanoff L, O'Donnell CJ, Camargo CA, O'Halloran TD, Giugliano RP, Lloyd-Jones DM. Usefulness of the TIMI Risk Index in predicting short- and long-term mortality in patients with acute coronary syndromes. Am J Cardiol 2005; 96:773-7
  13. Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction 3 and 4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44:783-9.
  14. Bradshaw PJ, Ko DT, Newman AM, Donovan LR, Tu JV. Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients. Can J Cardiol 2007; 23: 51-6
  15. Gourlay SG, Rundle AC, Barron HV. Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2). Nicotine Tob Res 2002; 4: 101-7.
  16. Weisz G, Cox DA, Garcia E, et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. Am Heart J 2005; 150: 358-64

External links


Template:WikiDoc Sources Template:Mdr